![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, March 13, 2017 3:15:46 PM
I'm not asking these questions to challenge HC, only to raise a point to current and potential investors about the concept "barriers to entry". The value to the CSL is there were only 18 companies approved when Abattis PR'd the license. My point was...if this so lucrative, and apparently you don't even need a scientist or functional lab to get a license, then how long can Abattis truly capitalize on this opportunity before other more respected cannabis companies jump into the testing market? And will NV even be operational in time to fully capitalize on "first mover status", to gain customers, establish trust, enjoy premiums on price, etc.
Only chance IMO is to get purchased by an LP who wants to make a long term investment in Quality Control to reduce their incremental cost per batch. I suppose if Experion executes their MMPR then Abattis can enjoy 25% of it, but that is a long ways off.
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM